Skip to content
stoqly

Sabra Health Care REIT

SBRA Nasdaq Health Care REITs Financials FY2016–FY2025

Sabra Health Care REIT's revenue rose 10.2% to $775 million in fiscal 2025. Its net margin was 20.1%, up from 18.0% a year earlier. It paid out $290 million in dividends and buybacks. The diluted share count rose 3.6%.

Last close · Oct 23, 2026

$19.56

0.2%
Value it Compare
Revenue Total sales reported in the income statement.
$775M
10.2% vs prior year
Operating margin Operating income as a share of revenue.
—
Net income Profit after all expenses, interest and tax.
$156M
22.8%
Free cash flow Cash from operations minus capital spending.
—
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
5.1%
0.4 pts
Market cap Last close times the latest diluted share count, so it is approximate.
$4.9B
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
75.2x
On $0.26 EPS (TTM)

What Sabra Health Care REIT does

No business description yet.

Legal name
SABRA HEALTH CARE REIT, INC.
Fiscal year ends
December 31, 2025
Latest annual report
—
Accession · CIK
0001492298-26-000008
0001492298

Revenue and margins

Sabra Health Care REIT had $775M of revenue in fiscal 2025, up 10.2% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

From fiscal 2016 to 2025, diluted EPS grew −4.0% a year. Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was — in fiscal 2025, — of revenue. Cash from operations minus capital spending.

Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Sabra Health Care REIT returned $290M to shareholders in fiscal 2025. The diluted share count rose 3.6%.

Dividends and buybacks
Dividends Buybacks
Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Value Sabra Health Care REIT yourself

Change the assumptions and see what they imply per share. These are models, not forecasts or price targets — the answer depends entirely on what you put in.

Discounted cash flow

Value per share

—

Adds net cash of −$2.5B and divides by 244.5M diluted shares. Ten years of cash flows plus a terminal value, discounted to today.

Earnings multiple

Value per share

—

Reference multiples: today 75.2x · peers 22.9x · sector 27.8x.

Balance sheet

Cash, debt and the ratios that show how comfortably Sabra Health Care REIT can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $112M$49.3M$41.3M$60.5M$71.5M
Debt incl. finance leases $2.4B$2.5B$2.4B$2.4B$2.5B
Net debt / EBITDA 6.4x7.8x7.5x5.7x5.4x
Debt / equity 0.7x0.8x0.9x0.9x0.9x
Interest coverage 1.8x1.2x1.2x2.1x2.4x
Total assets $6.0B$5.7B$5.4B$5.3B$5.5B
Total liabilities $2.6B$2.7B$2.6B$2.6B$2.7B
Shareholders' equity $3.4B$3.1B$2.8B$2.7B$2.8B
Net debt (− = net cash) $2.3B$2.5B$2.4B$2.4B$2.5B

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$4.5M

2 insiders

Of sales under plans

93%

$4.2M

DateInsiderTradeSharesPriceValueFiling
Sep 8, 2026 Richard K MatrosChair, CEO and President, Director Sold plan 200,000 $20.83 $4.2M Form 4
Mar 25, 2026 Jessica FloresExecutive VP & CAO Sold 15,231 $19.86 $0.3M Form 4

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

TestFY23FY24FY25
Net income is positive ✓ ✓ ✓
Cash from operations is positive ✓ ✓ ✓
Return on assets rose ✓ ✓ ✓
Cash from operations exceeds net income ✓ ✓ ✓
Debt fell relative to assets ✕ ✕ ✕
Current ratio rose — — —
Share count didn't rise ✕ ✕ ✕
Gross margin rose — — —
Revenue rose relative to assets ✓ ✓ ✓
F-score — / 9— / 9— / 9
Accruals ratio −5.2%−3.4%−3.6%
Altman Z'' ———

Similar companies

Each company's latest fiscal year. Fiscal years end in different months, so periods don't line up exactly.

CompanyMarket capGrowthOp. marginFCF marginROICP/EF-score
Sabra Health Care REIT SBRA $4.9B 10.2% — — 5.1% 75.2x —
Healthcare Realty Trust HR $6.1B −6.9% — 10.8% — — — Compare →
Omega Healthcare Investors OHI $14.6B 13.2% — 67.0% 8.8% 16.5x — Compare →
CareTrust REIT CTRE $8.6B 60.8% — — 9.3% 22.9x — Compare →
American Healthcare REIT AHR $10.2B 9.2% 18.4% — — 78.0x — Compare →

10 years of figures

US$ millions unless stated. Hover a ratio's name for its definition.

Download CSV
Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $261M $408M $623M $662M $599M $570M $625M $648M $703M $775M
Interest expense $64.9M $88.4M $147M $127M $100M $98.6M $106M $113M $115M $113M
Pretax income $71.3M $159M $288M $79.2M $156M $80.7M $21.7M $18.7M $128M $153M
Income tax $1.0M $0.7M $3.0M $3.4M $0.7M $1.8M $1.2M $2.0M $1.0M $1.8M
Net income $70.3M $158M $279M $69.0M $138M −$113M −$77.6M $13.8M $127M $156M
Diluted EPS $0.92 $1.40 $1.51 $0.37 $0.67 −$0.52 −$0.34 $0.06 $0.54 $0.64
Diluted shares 0.07B 0.11B 0.18B 0.19B 0.21B 0.22B 0.23B 0.23B 0.24B 0.24B
Cash flow
Cash from operations $176M $136M $361M $373M $355M $356M $316M $301M $311M $349M
Depreciation and amortization $68.5M $114M $191M $182M $177M $179M $188M $183M $170M $187M
Stock-based compensation $7.5M $8.4M $7.6M $9.8M $7.9M $7.9M $7.5M $7.9M $9.0M $11.4M
Acquisitions $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Share buybacks $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Dividends paid $119M $182M $325M $335M $278M $263M $277M $277M $280M $290M
Dividends and buybacks $119M $182M $325M $335M $278M $263M $277M $277M $280M $290M
Balance sheet
Cash and short-term investments $25.7M $519M $50.2M $39.1M $59.1M $112M $49.3M $41.3M $60.5M $71.5M
Total debt $1.2B $3.4B $3.2B $2.4B $2.4B $2.4B $2.5B $2.4B $2.4B $2.5B
Finance lease liabilities $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Inventory $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Total assets $2.3B $7.0B $6.7B $6.1B $6.0B $6.0B $5.7B $5.4B $5.3B $5.5B
Total liabilities $1.3B $3.6B $3.4B $2.6B $2.6B $2.6B $2.7B $2.6B $2.6B $2.7B
Shareholders' equity $1.0B $3.4B $3.3B $3.5B $3.4B $3.4B $3.1B $2.8B $2.7B $2.8B
Margins
EBITDA margin 78.5% 88.5% 100.4% 58.5% 72.3% 62.9% 50.4% 48.6% 58.7% 58.5%
Net margin 27.0% 38.8% 44.8% 10.4% 23.1% −19.9% −12.4% 2.1% 18.0% 20.1%
Returns
Return on capital 5.8% 5.8% 6.8% 3.2% 4.4% 3.1% 2.1% 2.2% 4.7% 5.1%
Return on equity 6.8% 7.1% 8.4% 2.1% 4.0% −3.3% −2.4% 0.5% 4.6% 5.6%
Return on assets 3.0% 3.4% 4.1% 1.1% 2.3% −1.9% −1.3% 0.3% 2.4% 2.9%
Growth
Revenue growth 9.1% 56.7% 52.7% 6.2% −9.6% −4.9% 9.7% 3.6% 8.6% 10.2%
Net income growth −11.5% 125.4% 76.2% −75.3% 100.6% −181.8% — — 821.1% 22.8%
EPS growth −17.1% 52.2% 7.9% −75.5% 81.1% −177.6% — — 800.0% 18.5%
Share count change 4.9% 61.5% 68.9% 5.3% 10.2% 5.7% 5.4% 0.8% 1.4% 3.6%
Financial health
Net debt / EBITDA 5.8x 8.0x 5.1x 6.1x 5.3x 6.4x 7.8x 7.5x 5.7x 5.4x
Debt / equity 1.2x 1.0x 1.0x 0.7x 0.7x 0.7x 0.8x 0.9x 0.9x 0.9x
Interest coverage 2.1x 2.8x 3.0x 1.6x 2.6x 1.8x 1.2x 1.2x 2.1x 2.4x
Capital allocation
Stock comp / revenue 2.9% 2.1% 1.2% 1.5% 1.3% 1.4% 1.2% 1.2% 1.3% 1.5%
Quality scores
Accruals ratio −4.5% 0.5% −1.2% −4.8% −3.6% −7.9% −6.7% −5.2% −3.4% −3.6%

Source: SEC EDGAR XBRL filings (CIK 0001492298). Data updated October 18, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move · ↵ to open